working to overcome the global impact of neglected … to overcome the global impact of neglected...

Update 2011

Working to overcome the global impact

of neglected tropical diseases

Update 2011

Updated_NTD_report2011_CS3_ok.indd iUpdated_NTD_report2011_CS3_ok.indd i 2011-10-14 16:35:132011-10-14 16:35:13

© World Health Organization 2011

All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specifi c companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

WHO/HTM/NTD/2011.3

i

Update 2011

ontents

Message from the Director iii

Neglected tropical diseases in the world today 1

Dengue 1

Trachoma 3

Buruli ulcer (Mycobacterium ulcerans infection) 4

Leprosy (Hansen disease) 5

Human African trypanosomiasis (sleeping sickness) 6

Dracunculiasis (guinea-worm disease) 8

Lymphatic fi lariasis 9

Onchocerciasis (river blindness) 10

Schistosomiasis (bilharziasis) 11

Soil-transmitted helminthiases 12 Preventive chemotherapy for helminthiases 13

WHO regional offi ces 14

C

Updated_NTD_report2011_CS3_ok.indd iUpdated_NTD_report2011_CS3_ok.indd i 2011-10-14 16:35:302011-10-14 16:35:30

ii

First WHO report on neglected tropical diseases

Updated_NTD_report2011_CS3_ok.indd iiUpdated_NTD_report2011_CS3_ok.indd ii 2011-10-14 16:35:302011-10-14 16:35:30

iii

Update 2011

Message from the Director

It is a year to the day since the World Health Organization (WHO) published its fi rst report on neglected tropical diseases. Almost always out of sight and rarely in news headlines, neglected tropical diseases are found

exclusively among poor populations in deprived rural communities. They cause misery and disability, sometimes life-long, to hundreds of millions of people worldwide.

Working to overcome the global impact of neglected tropical diseases, launched by WHO on 14 October 2010, provides evidence that existing safe, simple and effective interventions, implemented during the past seven years, are improving the health and quality of life of populations in 149 countries where many of the 17 diseases1 occur. Approximately 90% of their burden can be treated with medicines administered only once or twice a year.

Evidence also demonstrates that control of neglected tropical diseases signifi cantly reduces illness, social exclusion and mortality. Furthermore, prevention and control directly contributes to improved economic productivity and the achievement of several of the United Nations Millennium Development Goals.

In her address during the launch of the report, WHO Director-General Margaret Chan spoke of current “breakthrough” strategies to reduce the burden of these diseases. Accelerated efforts are needed to break the cycle of infection and disability, which mire people in poverty. Dr Chan challenged the international community to show greater resolve in control of these diseases, and to produce “results”.

One year on and accelerating work to overcome neglected tropical diseases

1 The 17 neglected tropical diseases are: dengue, rabies, trachoma, Buruli ulcer (Mycobacterium ulcerans infection), endemic treponematoses, leprosy (Hansen disease), Chagas disease (American trypanosomiasis), human African trypanosomiasis (sleeping sickness), leishmaniasis, cysticercosis, dracunculiasis (guinea- worm disease), echinococcosis, foodborne trematode infections, lymphatic fi lariasis, onchocerciasis (river blindness), schistosomiasis (bilharziasis) and soil-transmitted helminthiases.

Updated_NTD_report2011_CS3_ok.indd iiiUpdated_NTD_report2011_CS3_ok.indd iii 2011-10-14 16:35:302011-10-14 16:35:30

iv


Today, we are continuing to make signifi cant progress against neglected tropical diseases, some of which maim, cause anaemia, stunt children’s growth and compromise pregnancy outcomes. It is now known that urogenital schistosomiasis in women causes long-term irreversible consequences, including infertility. Many women in areas endemic for urogenital schistosomiasis have female genital schistosomiasis. There is also the plausibility of a possible link between female genital schistosomiasis and HIV acquisition in women. An increase in coverage of large-scale preventive treatment (preventive chemotherapy) for schistosomiasis will signifi cantly decrease morbidity. and may prevent transmission of HIV and other sexually transmitted infections.

Provisional fi gures show that of the estimated 32 million people who were treated for schistosomiasis worldwide in 2010, 28 million were in sub-Saharan Africa, where the disease is widely distributed. Results of recent surveys conducted in Morocco, using the most sensitive diagnostic techniques, show that none of the 2300 children aged under 16 years from formerly endemic areas had been re-exposed to the infection, confi rming the interruption of

transmission of urogenital schistosomiasis. No screened vector snails harboured the parasite.

We are now on the verge of eradicating dracunculiasis, the fi rst parasitic disease to be wiped out. To bolster the fi nal phases of eradication, and despite the global fi nancial crisis, on 5 October 2011 the Government of the United Kingdom announced a challenge grant of UK£ 20 million (approximately US$ 32 million) to enable The Carter Center and WHO to fi nish the job. This pledge is widely expected to encourage other donors to come forward and match the additional funding required. Under current conditions, WHO and The Carter Center estimate that at least USD$ 70 million is needed to achieve complete interruption of transmission by 2015 in the four countries where cases are still occurring. A further mandatory period of three years is needed from the time the last country interrupts transmission to certify eradication.

Signifi cant progress has been made for other neglected tropical diseases for which active surveillance and individualized treatment are required. The introduction of combination antibiotic therapy has reduced by about 30% the need for surgery for people affected by Buruli ulcer.

Systematic screening and treatment of at-risk populations have reduced cases of human African trypanosomiasis (sleeping sickness) to their lowest level

Dr Lorenzo SavioliDirector Department of Control of Neglected Tropical DiseasesWorld Health Organization

Despite a diffi cult economic outlook, we believe that immense opportunities exist for investing in the health of poor populations to improve their health and reduce poverty. With a fi rmer resolve and the right interventions, WHO is confi dent that the burden of many of these diseases will be substantially reduced or eliminated by 2020.

“

”Updated_NTD_report2011_CS3_ok.indd ivUpdated_NTD_report2011_CS3_ok.indd iv 2011-10-14 16:35:302011-10-14 16:35:30

v

Update 2011

in 50 years. In 2010, there were 7139 new cases, compared with 9878 cases in 2009, a decrease of 28% in just one year.

Sustained vector control has largely contributed to reducing transmission of Chagas disease in Latin America and has helped save millions from chronic impairments. Between 2007 and 2010, 2 million nifurtimox tablets were distributed for second-line treatment. During the same period, 30 000 patients in endemic countries received fi rst-line treatment with benzidazole. Moreover, WHO is leading a global awareness campaign in response to the spread of Chagas disease outside Latin America. An informal non-endemic countries initiative for addressing this problem was established in 2007.

Immediate intervention by WHO in providing medicines, logistics and support during an outbreak of visceral leishmaniasis in South Sudan in 2010 and early 2011 enabled the treatment of 60% of the total 12 000 patients; the case-fatality rate was 5% compared with that of 95% in the 1990s. Early and appropriate treatment averts death from visceral leishmaniasis or the stigma of cutaneous leishmaniasis. Regional control programmes, particularly on the Indian subcontinent, have strengthened capacity-building, access to medicines and surveillance over the past fi ve years. Similar programmes have now been launched in the Region of the Americas, the Eastern Mediterranean Region and the European Region.

Today, dengue ranks as the most important mosquito-borne viral disease in the world, with nearly 3 billion people at risk in over 100 countries. A WHO survey in 2010 revealed that since 2005, the WHO-recommended policy of integrated vector management has been adopted in 68 of 110 participating countries. This integrated vector management approach for dengue has benefi tted more than 20 million people in three WHO regions (the Western Pacifi c Region, the South-East Asian Region and the Region of the Americas). WHO also supports capacity-building for clinical management of severe dengue cases in all regions.

WHO advocates integrated vector management as an approach to control dengue fever, Chagas disease and lymphatic fi lariasis. In early 2011, WHO published a position paper on Integrated Vector Management to control lymphatic fi lariasis and malaria, which promotes the integrated use of effective vector control measures to control and eliminate lymphatic fi lariasis in areas in central Africa where Loa loa is concurrently endemic.

Management of pesticides used in public health is a priority for WHO as integrated vector management emerges as the major component of a strategy to facilitate the sustainable use of pesticides and the reduction of associated health risks. Between 2008 and 2010, the WHO Pesticide Evaluation Scheme (WHOPES) supported 13 WHO Member States to develop national action plans for sound management of pesticides for public health. Furthermore, standards of pesticide quality developed by WHOPES are currently being used in 96 countries where vector-borne diseases are endemic.

Updated_NTD_report2011_CS3_ok.indd vUpdated_NTD_report2011_CS3_ok.indd v 2011-10-14 16:35:312011-10-14 16:35:31

vi


WHO has provided technical expertise to support pilot projects in eliminating human and canine rabies in KwaZulu Natal (South Africa), the United Republic of Tanzania and the Visayas archipelago in the Philippines. The projects aim to demonstrate that human rabies can be prevented in different settings by controlling the disease in dogs. Preliminary results in June 2011 show that for the fi rst time, zero cases of human rabies have been reported for 12 consecutive months. The number of human rabies cases is also decreasing in the western Visayas in the Philippines. Since the start of the project, more than 4 million doses of dog rabies vaccines have been provided to the three areas for mass vaccination. As part of the project, and for the fi rst time in Africa, an economical regimen for post-exposure prophylaxis (PEP) has been introduced and incorporated into the Tanzania national PEP guidelines.

There is an increasing need for greater involvement of public-health veterinarians at the animal–human interface as much of the morbidity and mortality resulting from neglected tropical diseases has a major zoonotic component. Veterinary public health is supporting a paradigm shift in global approaches to the control of diseases originating at the animal–human interface, emphasizing control at the animal source.

In July 2011, WHO organized an interagency meeting with the Food and Agriculture Organization of the United Nations and the World Organization for Animal Health to defi ne a “priority neglected zoonotic diseases investment portfolio” and formulate a roadmap to tackle them. The minimum investment required is estimated at US$ 20 million a year for the 5-year period 2012–2016.

WHO continues to advocate free and timely access to high-quality medicines and preventive diagnostic tools through an intersectoral, interprogrammatic approach and the consolidation of partnerships and resource mobilization. It has long advocated the need for donations of essential medicines to enable wider access to treatment for poor populations. Pharmaceutical companies responded favourably to the Director-General’s call for an increase in donated medicines during the October 2010 launch of the report by making important pledges. We can now proudly say that almost all of these pledges have been confi rmed.

Control of neglected tropical diseases today relies on two pillars: access to treatment with safe and effective medicines available free of charge to affected populations, and judicious use of pesticides for vector control. Although prospects for scaling-up interventions look promising, there are challenges that remain.

Many countries where soil-transmitted helminthiases are endemic have not attained the target set for 2010 by World Health Assembly resolution WHA54.19, and adopted in 2001, to treat at least 75% of school-aged children at risk of morbidity. In 2009, only 31% of all children at risk of soil-transmitted helminthiases received preventive chemotherapy treatment.

Updated_NTD_report2011_CS3_ok.indd viUpdated_NTD_report2011_CS3_ok.indd vi 2011-10-14 16:35:312011-10-14 16:35:31

vii

Update 2011

With the projected greater availability of funding and donated medicines, WHO plans to scale up integrated preventive treatment of soil-transmitted helminthiases and schistosomiasis to reach a minimum of 75% coverage of all children by 2020.

WHO estimates that US$ 1.7 billion may be needed over the next 5 years to treat all populations at risk of contracting one of the following neglected tropical diseases: lymphatic fi lariasis, onchocerciasis, soil-transmitted helminthiases (ascariasis, hookworm infections and trichuriasis), schistosomiasis and trachoma. Supplies of donated medicines such as praziquantel and funds for its production are currently insuffi cient to meet demand for the control of schistosomiasis, which affects more than 240 million people worldwide. Two billion tablets might be required over the next 5 years. This means that the amount of donated praziquantel needs to increase at least 10–20 times to increase coverage in Africa at a level similar to that of other donated medicines. Today, praziquantel is the only commercially available treatment for human schistosomiasis. It is currently off patent, and most of the active pharmaceutical ingredient is produced in China.

There is also a need for additional treatment facilities to be made available for complex diseases. This will require health-care systems to provide wider access to available medicines and increased capacity for surgical interventions. Success in controlling visceral leishmaniasis involves an increase in capacity for early case-fi nding and timely delivery of oral treatment.

With cases of human African trypanosomiasis at their lowest level in 50 years, there is need now more than ever to maintain sustained control and surveillance activities using the best, albeit imperfect, tools available. We must ensure that endemic countries integrate surveillance activities in their services while retaining the capacity to react rapidly to the results of surveillance outcomes. Lesson learnt from the past should be heeded: in the 1980s, the disease re-emerged in many regions after decades of successful control activities.

Control of Chagas disease requires the strengthening of the current global epidemiological surveillance to prevent all forms of transmission and detection. Although nifurtimox is provided free of charge through WHO to all endemic countries, securing adequate provision of benznidazole poses a major challenge.

For Buruli ulcer, specifi c approaches such as community education and awareness campaigns need to be developed to encourage early reporting and detection, and enable timely intervention. The introduction in 2006 of combination antibiotic therapy to treat the early stages of the infection has shown promising results.

Feasible and complete interruption of yaws transmission has not been achieved because control programmes were halted in many endemic countries. Active case-fi nding and a single injection of benzylpenicillin are

Updated_NTD_report2011_CS3_ok.indd viiUpdated_NTD_report2011_CS3_ok.indd vii 2011-10-14 16:35:312011-10-14 16:35:31

viii


suffi cient to cure the disease and reduce transmission of its pathogen. The main challenge remains the epidemiological assessment and implementation of control activities in WHO’s African Region.

Another area of challenge is sustaining new methods of vector control, as evidenced by recent dengue outbreaks in various regions of the world. More resources are needed to scale up activities at the country level and to develop a new global strategic plan for dengue prevention and control.

Despite a diffi cult economic outlook, we believe that immense opportunities exist for investing in the health of poor populations to improve their health and reduce poverty. With a fi rmer resolve and the right interventions, WHO is confi dent that the burden of many of these diseases will be substantially reduced or eliminated by 2020.

Dr Lorenzo SavioliDirector

Department of Control of Neglected Tropical DiseasesWorld Health Organization

- GlaxoSmithKline (GSK) is expanding their donation of albendazole by 400 million tablets a year over the next 5 years starting in 2012. This additional donation mainly aims to treat children for intestinal worms and comes on top of the 600 million tablets of albendazole from GSK already being used in the Global Programme to Eliminate Lymphatic Filariasis. Combined, this latest increase brings to 1 billion the annual number of albendazole tablets donated by GSK.

- Sanofi renewed in March 2011 its agreement to donate an unlimited quantiry of efl ornithine, melarsoprol and pentamidine for the treatment of human African trypanosomiasis. It is also contributing US$25 million over a period of fi ve years (2011-2016) to support WHO’s human African trypanosomiasis control programme. Sanofi -aventis also supports control programmes for other diffi cult-to-treat diseases such as Buruli ulcer, Chagas disease, leishmaniasis and yaws.

- Bayer signed an agreement with WHO on 4 March 2011 increasing its donation of nifurtimox from its current 2.5 million tablets over fi ve years to 5 million tablets until 2017. This is meant for the treatment of Chagas disease and human African trypanosomiasis. Bayer which also donates an unlimited quantity of suramin for human African trypanosomiasis (HAT) will continue its cash contribution to fund logistics and distribution of medicines.

- Johnson & Johnson is expanding its current donation of 50 million treatments of mebendazole per year to 200 million annually.

- Novartis is continuing to donate multidrug therapy (rifampicin, clofazimine and dapsone in blister packs) and loose clofazimine to all leprosy patients worldwide until the end of 2015. The company is also donating triclabendazole for the treatment of fascioliasis - an animal infection caused by parasitic fl atworms that is transmitted to humans.

- Pfi zer will continue to donate an unlimited quantity of azithromycin for the treatment of trachoma while Merck & co. Inc gives an unlimited supply of ivermectin for as long as needed directly to countries for lymphatic fi lariasis and onchocerciasis.

- Another landmark donation is that of praziquantel from Merck KGaA which is currently making available to WHO 200 million tablets for the control of schistosomiasis until 2017.

Updated_NTD_report2011_CS3_ok.indd viiiUpdated_NTD_report2011_CS3_ok.indd viii 2011-10-14 16:35:312011-10-14 16:35:31

1

Update 2011

Neglected tropical diseases in the world today

Dengue

Countries or areas at risk of dengue transmission

Distribution of countries or areas at risk of dengue transmission, worldwide, 2010

1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010

2.5

2

1.5

1

0.5

0

Year

Nu

mb

er o

f ca

ses

rep

ort

ed

(m

illio

ns)

AMR – The Americas

SEAR – South-East Asia

WPR – Western Pacifi c

Number of cases of dengue reported to WHO, 1995–2010

Updated_NTD_report2011_CS3_ok.indd 1Updated_NTD_report2011_CS3_ok.indd 1 2011-10-14 16:35:312011-10-14 16:35:31

2


2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010

4 500

4 000

3 500

3 000

2 500

2 000

1 500

1 000

500

0

Year

Nu

mb

er o

f d

eath

s re

po

rte

d




Number of dengue deaths reported to WHO, 2000–2010


3

Update 2011

Trachoma

Distribution of trachoma, worldwide, 2010

Countries or areas endemic for blinding trachoma

Countries or areas under surveillance

Not applicable

2006 2007 2008 2009

50

45

40

35

30

25

20

15

10

5

0

Year

Nu

mb

er o

f p

eop

le t

reat

ed

(m

illio

ns)

AFR – African


EMR – Eastern Mediterranean



Number of people treated for trachoma, 2006–2009

WHO Region AFR AMR EMR SEAR WPR Global

Number of people treated in 2009 40 936 310 60 000 691 296 3 251 697 10 000 44 949 303


4


Buruli ulcer (Mycobacterium ulcerans infection)

Number of reported cases, 2010

Distribution of Buruli ulcer, worldwide, 2010

Not applicable

>1 000

500–999

100–499

<100

Previously reported cases

No cases reported

2004 2005 2006 2007 2008 2009 2010

5500

5400

5300

5200

5100

5000

4900

4800

4700

4600

Year

Nu

mb

er o

f n

ew c

ases

rep

ort

ed

Global number of new cases of Buruli ulcer reported to WHO, 2004–2010


5

Update 2011

Leprosy (Hansen disease)Leprosy prevalence rates, data reported to WHO as of beginning January 2011

>2

1.0 - 2.0

<1

No data available

0 cases reported

Prevalence rates (per 10 000 population)

Not applicable

1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010

900

800

700

600

500

400

300

200

100

0

Year

Nu

mb

er o

f n

ew c

ase

s re

po

rte

d (

tho

usa

nd

s)

Global number of new cases of leprosy reported to WHO, 1991–2010


6


Human African trypanosomiasis (Sleeping sickness)

>1 000

100–1 000

<100

Endemic countries (no data available)

Non T. b. gambiense endemic countries


0 cases reported

Not applicable

Distribution of human African trypanosomiasis (T.b. gambiense), worldwide, 2010


Distribution of human African trypanosomiasis (T.b. rhodesiense), worldwide, 2010

Not applicable

>100

<100

0 cases reported

Endemic countries (no data available)

Non T.b. rhodesiense endemic countries


7

Update 2011

1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010

40000

35000

30000

25000

20000

15000

10000

5000

0

Year

Nu

mb

er o

f n

ew c

ase

s re

po

rte

d (

tho

usa

nd

)

Global number of new cases of human African trypanosomiasis reported to WHO, 1990–2010

WHO Region AFR EMR Global

Total number of new cases reported in 2010 6 939 200 7 139

AFR – African



8


Dracunculiasis (guinea-worm disease)Status of dracunculiasis eradication, worldwide, as of June 2011

Not applicable

Countries currently endemic for dracunculiasis

Countries in the precertification stage

Previously endemic countries certified free of dracunculiasis

Other countries and territories certified free of dracunculiasis

Countries and territories not known to have dracunculiasis but yet to be certified

Countries reporting cases in 2011

Note: Chad - country in the precertification stage had an outbreak since 2010

1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010

1000

800

600

400

200

0

Year

Nu

mb

er o

f n

ew c

ase

s re

po

rte

d (

tho

usa

nd

s)

Annual incidence of dracunculiasis, by WHO region, 1989-2010

WHO Region AFR EMR SEAR Global

Total number of new cases reported in 2010 99 1 698 0 1 797

AFR – African



2004 2005 2006 2007 2008 2009 2010

30

20

10

0

Year

Nu

mb

er o

f n

ew c

ase

s re

po

rte

d (

tho

usa

nd

s)

Annual incidence of dracunculiasis, by WHO region, 2004-2010


9

Update 2011

Lymphatic fi lariasis

Endemic countries and territories implementing MDA *

Endemic countries and territories

Endemic countries and territories where the target was achieved and MDA stopped

Not applicable

Non-endemic countries and territories

Distribution and status of preventive chemotherapy for lymphatic filariasis, worldwide, 2010

* MDA - Mass Drug Administration

2004 2005 2006 2007 2008 2009

60

50

40

30

20

10

0

Year

Co

vera

ge

(%)

Reported coverage of treatment for lymphatic fi lariasis, by WHO region, 2004–2009

WHO Region AFR AMR EMR SEAR WPR Total

Number of people treated in 2009 69 131 743 3 364 031 25 000 395 934 743 16 774 365 485 229 882

AFR – African





Global


10


Onchocerciasis (river blindness)

Meso or hyper endemic (prevalence >=20%)

Hypo-endemic (prevalence <20%)

Endemic countries (former OCP countries)

Non-endemic countries

Distribution of onchocerciasis, worldwide, 2010

Not applicable

2005 2006 2007 2008 2009

60

80

70

60

50

40

30

20

10

0

Year

Co

vera

ge

(%)

Reported coverage of treatment for onchocerciasis, by WHO region, 2005–2009

WHO Region AFR AMR EMR Global

Number of people treated in 2009 65 408 388 314 444 3 011 429 68 734 261

AFR – African



Global


11

Update 2011

Schistosomiasis (bilharziasis)

High (prevalence >=50%)

Moderate (prevalence >=10% to <50%)

Low (prevalence <10%)

Non-endemic countries or territories

Not applicable

Distribution of schistosomiasis, worldwide, 2010

2006 2007 2008 2009

60

20

15

10

5

0

Year

Nu

mb

er o

f p

eop

le t

reat

ed

(m

illio

ns)

Number of people treated for schistosomiasis and reported treatment coverage, by WHO region 2006–2009

WHO Region AFR AMR EMR WPR Total

Number of people treated in 2009 14 735 638 30 418 2 551 316 2 642 207 19 959 579

AFR – African




Global coverage

Co

vera

ge

(%)

10

8

6

4

2


12


Soil-transmitted helminthiases

<1/3

1/3 - 2/3

>2/3

No data available

No PC required

Proportion of children (1-15 years of age) in the country requiring preventive chemotherapy for soil-transmitted helminthiases

Not applicable

Distribution of soil-transmitted helminthiases, worldwide, 2010

2004 2005 2006 2007 2008 2009

50

45

40

35

30

25

20

15

10

5

0

Year

Co

vera

ge

(%)

Reported coverage of treatment for soil-transmitted helminthiases, by WHO region, 2004–2009

WHO Region AFR AMR EMR EUR SEAR WPR Total

Number of people treated in 2009 103 186 098 39 160 613 2 513 093 789 413 154 139 343 14 304 492 314 093 053

AFR – African





Global

In the WHO European region 11 countries are endemic. Interventions are not done every year.

New estimates of people requiring PC for STH – Soil-transmitted helminthiases: estimates of the number of children needing preventive chemotherapy

and number treated, 2009. WER, N°25, 2011, 86:257–268.


13

Update 2011

Preventive chemotherapy for helminthiases

WHO region Number of countries Number of people treated for Number of people reporting to WHO reached by Lymphatic fi lariasis Soil-transmitted Schistosomiasis Onchocerciasis preventive chemotherapy helminthiases for at least one disease

African 34 69 131 743 103 186 098 14 735 638 65 408 388 200 788 299

Americas 17 3 364 031 39 160 613 30 418 314 444 40 934 175

Eastern Mediterranean 7 25 000 2 513 093 2 551 316 3 011 429 5 699 204

European 2 789 413 789 413

South-East Asia 7 395 934 743 154 139 343 428 623 308

Western Pacifi c 10 16 774 365 14 304 492 2 642 207 28 250 061

GLOBAL 77 485 229 882 314 093 053 19 959 579 68 734 261 705 084 460

2005 2006 2007 2008 2009 2005 2006 2007 2008 2009 2005 2006 2007 2008 2009 2005 2006 2007 2008 2009

70

60

50

40

30

20

10

0

Year

Co

vera

ge

(%)

Global coverage (%) of preventive chemotherapy for schistosomiases, soil-transmitted helminthiases, lymphatic fi lariasis and onchocerciasis

Global coverage shown is the proportion of the population requiring preventive chemotherapy that has been treated. For soil-transmitted helminthiases

(STH) target population is children aged from 1 year to 15 years.

Source: WHO preventive chemotherapy and transmission control databank (available at

http://www.who.int/neglected_diseases/preventive_chemotherapy/databank/en/ ).

Schistosomiasis Soil-transmitted helminthiases Lymphatic fi lariasis Onchocerciasis


14


WHO regional offi ces

Regional Offi ce for AfricaCité du Djoué, P.O.Box 06Brazzaville, CongoTelephone: + 242 839 100 / +47 241 39100Facsimile: + 242 839 501 / +47 241 395018E-mail: [email protected]

Regional Offi ce for the Americas525, 23rd Street, N.W.Washington, DC 20037, USATelephone: +1 202 974 3000Facsimile: +1 202 974 3663E-mail: [email protected]

Regional Offi ce for South-East AsiaWorld Health HouseIndraprastha EstateMahatama Gandhi MargNew Delhi 110 002, IndiaTelephone: + 91-11-2337 0804Facsimile: + 91-11-2337 9507E-mail: [email protected]

Regional Offi ce for Europe8, Scherfi gsvejDK-2100 Copenhagen 0, DenmarkTelephone: + 45 39 171 717Facsimile: + 45 39 171 818E-mail: [email protected]

Regional Offi ce for the Eastern MediterraneanAbdul Razzak Al Sanhouri Street,P.O. Box 7608,Nasr City, Cairo 11371, EgyptTelephone: + 202 2276 50 00Facsimile: + 202 2670 24 92 or 2670 24 94E-mail: [email protected]

Regional Offi ce for the Western Pacifi cP.O. Box 29321000 Manila, PhilippinesTelephone: + 63 2 528 8001E-mail: [email protected]


15

Update 2011


working to overcome the global impact of neglected … to overcome the global impact of neglected...

Documents